New results from the EAACI 2026 congress showed remibrutinib effectively resolved chronic inducible urticaria, a difficult-to-treat allergic skin condition.
Tag: remibrutinib
Remibrutinib Resolves Chronic Urticaria in Phase III Trial Data Presented at EAACI
Phase III data from a large clinical trial confirmed that remibrutinib led to complete resolution of chronic inducible urticaria in most patients treated.